Malign Pleural Effusion In A Patient With Multiple Myeloma
MULTIPLE MYELOMLU HASTADA GELİŞEN MALÎN PLEVRAL EFFÜZYON

Abdullah KATGI¹, Selda KAHRAMAN¹, Pınar ATACA², Özden PIŞKİN¹, Mehmet Ali ÖZCAN¹, Güner Hayri ÖZSAN¹, Fatih DEMİRMKAN¹, BülentÜNDAR¹

¹Dokuz Eylül Üniversitesi Tıp Fakültesi, Hematoloji Anabilim Dalı
²Dokuz Eylül Üniversitesi Tıp Fakültesi, İç Hastalıklar Anabilim Dalı

ÖZET
Malign pleural effusion, multiple myeloma progression characterized and common complication. The mean survival time is four months after the diagnosis with a poor response to systemic chemotherapy. In this paper we mentioned about a 49 year old multiple myeloma patient in her fourth month of the diagnosis with a formation of malignant effusion just after induction chemotherapy and died because of respiratory failure.

Anahtar sözcükler: Multiple myeloma, pleural effusion

SUMMARY
Malign pleural effusion is a late and rare complication of multiple myeloma revealing the progression. The mean survival time is four months after the diagnosis with a poor response to systemic chemotherapy.

In this paper we mentioned about a 49 year old multiple myeloma patient in her fourth month of the diagnosis with a formation of malignant pleural effusion just after induction chemotherapy and died because of respiratory failure.

Key words: Multiple myeloma, Pleural effusion

ADDABEH KATGI
Dokuz Eylül Üniversitesi
Tıp Fakültesi
Hematoloji AD

Multiple Myeloma (MM) is a malignant disease defined as proliferation of neoplastic plasma cells, which replace the normal bone marrow and produce excessive amounts of immunoglobulin or light chain (1).

Pleural effusion is a rare complication develops approximately 6% of patients with MM during the course of their disease (2).

Pleural effusions in MM are usually benign and are due to congestive heart disease, chronic renal failure, hypoalbuminemia, cardiac amyloidosis, pulmonary infarctions or infections (2). Myelomatous involvement is a rare complication of a progressive disease (3).

We discussed a MM patient developed malignant pleural effusion under chemotherapy in this paper.

CASE REPORT

49 year old woman approached to neurosurgery clinic four months ago with severe back pain, difficulty in walking and fatigue. An excision was made from the solid...
extradural mass which was detected between T7-T10 vertebra by thoracal MR. Pathology resulted as plasma cell neoplasia. The patient was consulted to hematology department. Monoclonal gammopathy was shown in protein electrophoresis with serum immunoglobulin G (IgG) level as 5140 mg/dL (normal range between 552-1631). Beta 2 macroglobulin was 8432 mg/dL with hemoglobin: 5.9 gr/dL, MCV:92 fl, leukocyte:6600, platelet 148.000, creatinin: 0.75 mg/dl, ALT: 11 u/L AST: 16 u/L Ca: 9.2 mg/dL, Fosfor: 3.6 mg/dL, LDH: 657 U/L, CRP: 3.23 mg/dL, globulin: 6 g/dL. In bone marrow aspiration % 40 patological plasma cells was counted and the biopsy was diagnosed as Ig G Kappa multiple myeloma with stage 3A in Durie Salmon, stage 3 in ISS. No lytic lesions were detected in bone survey however radiotherapy was performed to L2-L5, T6-11 in case of collapsing fracture. The cyclophosphamide-dexamethasone chemotherapy and antiresorptive zolendronic acid was prescribed. After the second cure of cyclophosphamide-dexamethasone regimen respiratory distress was developed and massive pleural effusion detected in her right lung in the thoracal computerized tomography (Figure 1). In cytological evulation of pleural effusion by thoracentesis pathological plasma cell infiltration was discovered (Figure 2). Under present findings the patient treated like a progressive disease with second line chemotherapy cyclophosphamide-dexamethasone and bortezomib. The patient was dead in the fourth month of diagnosis because of the disease progression.

DISCUSSION

Involvement of the serous cavities is uncommon in MM and commonly documented sites of involvement in descending order of frequency are the pleural cavity, peritoneal cavity, cerebrospinal space and pericardium (4).

Myeloma is a very rare etiology of malignant pleural effusion. The mechanisms of malignant pleural effusion in myeloma have been proposed to be due to several causes: MPE results from direct pleural infiltration of myeloma cells from adjacent pulmonary or chest wall lesions, hematogenous spread and or lymphatic obstructions (5).

91 malignant myelomatous effusion cases reported until August 2005 worldwide (6). In a study analysing 57 of the cases showed that left pleural cavity was more commonly involved and IgG myeloma was the most common isotype associated with malignant pleural effusion opposite to early reviews pointing out IgA predominancy (7,8). Our patient was a IgG type myelom also.

The most effective method in the diagnosis of myelomatous pleural effusion is the cytological identification of malign plasma cells in pleural effusion (3). Plasma cells from the pleural fluid in our case showed typical basophilic cytoplasm with large, eccentric nuclei and prominent nucleoli.

Myelomatous pleural effusion in multiple myeloma has been thought as a late manifestation in the natural history or an expression of the aggressive behavior of the disease (9).

These patients have been found to respond poorly to available therapy and have short survivals following systemic chemotherapy. In literature, there are cases reported with transient improvement however mostly patients died in few months, the mean survival duration after a diagnosis of MPE is approximately 4 months (3,10).
In most of the patients MPE is detected at the time of treatment although MPE can be the initial presentation of MM. The appearance time of effusion is effecting directly on survival. In one metaanalysis showed that the mean survival in early presentation of MPE is two months on the other hand the mean survival in late presentation of MPE after MM diagnosis is 4 months (8).

In our patient myelomatous pleural effusion was detected in the forth month of diagnosis after the induction chemotherapy and she was died after 10 days because of respiratory failure.

In conclusion, in the case of MPE, aggressive treatment including novel agents or autologous stem cell transplantation should be considered, especially if MPE is the initial presenting manifestation of MM.

REFERENCES